Intrapharm Laboratories Ltd

intrapharmlabs.com

Founded in 1999, Intrapharm Laboratories is a rapidly expanding speciality pharmaceutical company with many years of experience in both the sales and marketing of pharmaceutical products in both the UK and Republic of Ireland. Innovative collaboration with both UK and international companies has lead to the successful commercialisation of many niche pharmaceutical and 'Over the Counter' products. Based in the United Kingdom, Intrapharm Laboratories is an important supplier to both the NHS and international markets ensuring the ongoing supply of pharmaceutical products with proven therapeutic value.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

OZETTE TECHNOLOGIES ANNOUNCES NEW COLLABORATION WITH UMOJA BIOPHARMA TO ACCELERATE BIOMARKER DISCOVERY IN PRECLINICAL STUDIES

Businesswire | June 28, 2023

news image

Ozette Technologies, Inc., a technology-driven life sciences company, announced its collaboration with Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers. Umoja will use Ozette’s AI-powered single-cell technology for their preclinical studies. As part of this work, the Ozette Platform™ will be used to provide research and development (R&D) support and evaluate biomarker endpoints fro...

Read More

Research

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

news image

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More

TELIX PHARMACEUTICALS ENTERS STRATEGIC COLLABORATION WITH VARIAN MEDICAL SYSTEMS FOR ADVANCED PROSTATE IMAGING

Telix Pharmaceuticals Limited | September 07, 2020

news image

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission to...

Read More

Business Insights

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

news image

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More
news image

Pharma Tech

OZETTE TECHNOLOGIES ANNOUNCES NEW COLLABORATION WITH UMOJA BIOPHARMA TO ACCELERATE BIOMARKER DISCOVERY IN PRECLINICAL STUDIES

Businesswire | June 28, 2023

Ozette Technologies, Inc., a technology-driven life sciences company, announced its collaboration with Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers. Umoja will use Ozette’s AI-powered single-cell technology for their preclinical studies. As part of this work, the Ozette Platform™ will be used to provide research and development (R&D) support and evaluate biomarker endpoints fro...

Read More
news image

Research

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More
news image

TELIX PHARMACEUTICALS ENTERS STRATEGIC COLLABORATION WITH VARIAN MEDICAL SYSTEMS FOR ADVANCED PROSTATE IMAGING

Telix Pharmaceuticals Limited | September 07, 2020

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission to...

Read More
news image

Business Insights

ORAMED COMPLETES PATIENT ENROLLMENT IN PHASE 2 ORAL INSULIN NASH TRIAL

Oramed Pharmaceuticals Inc. | March 17, 2022

Oramed Pharmaceuticals Inc. a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced it has completed enrollment of all patients in a Phase 2 trial of its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis. An estimated 1.5% to 6.5% of adults in the U.S., or between 4 million and 17 million people, have NASH and about half of these also have diabetes, according to the National Institute of Diabetes and Dige...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us